DK2552910T3 - Ny polymorf - Google Patents
Ny polymorf Download PDFInfo
- Publication number
- DK2552910T3 DK2552910T3 DK11714079T DK11714079T DK2552910T3 DK 2552910 T3 DK2552910 T3 DK 2552910T3 DK 11714079 T DK11714079 T DK 11714079T DK 11714079 T DK11714079 T DK 11714079T DK 2552910 T3 DK2552910 T3 DK 2552910T3
- Authority
- DK
- Denmark
- Prior art keywords
- solid form
- benzazepin
- proline
- tetrahydro
- benzylcarbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Claims (11)
1. Fast form af l-(2-methyl-4-(2,3,4,5-tetrahydro-l-benzazepin-l-ylcarbo-nyl)benzylcarbamoyl)-l-prolin-/V,/V-dimethylamid, der udviser mindst de følgende karakteristiske røntgen-pulver-diffraktionstoppe (Cu Κα-stråling, udtrykt i grader 2Θ) ved ca. 5,5, 10,9, 14,2, 21,9 og 24,0.
2. Den faste/Fast form ifølge krav 1 der har et røntgen-pulver-diffraktionsmønster med i det væsentlige det samme som det der er vist i figur 1.
3. Fast form ifølge krav 1 eller 2 der er kendetegnet ved et IR-spektrum med toppe udtrykt i cm 1 ved ca. 3525, 3425, 2932, 2873, 2135, 1958, 1925, 1631, 1529, 1489, 1439, 1377, 1355, 1311, 1260, 770, 743.
4. Fast form ifølge et hvilket som helst af kravene 1 til 3 med et IR-spektrum med i det væsentlige det samme som det der er vist i figur 3.
5. Fast form ifølge et hvilket som helst af kravene 1 til 4 der er et hydrat.
6. Fast form ifølge krav 5, hvor hydratet er et monohydrat.
7. Farmaceutisk sammensætning omfattende en fast form ifølge et hvilket som helst af kravene 1 til 6, eller et solvat deraf, i forbindelse med en farmaceutisk acceptabelt adjuvans, diluent eller bærer.
8. Fast form ifølge et hvilket som helst af kravene 1 til 6, eller et solvat deraf, til anvendelse i terapi.
9. Fast form ifølge et hvilket som helst af kravene 1 til 6, eller et solvat deraf, til anvendelse i behandling af en sygdom eller tilstand medieret af vasopressin V2-receptorer.
10. Fast form til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden medieret af vasopressin V2-receptorer er valgt fra nocturnal enuresis, nocturia, polyuria som resultat af central diabetes insipidus, urininkontinens og blødningsforstyrrelser.
11. Fast form til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden medieret af vasopressin V2-receptorer er nocturia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2552910T3 true DK2552910T3 (da) | 2015-04-07 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11714079T DK2552910T3 (da) | 2010-04-01 | 2011-03-31 | Ny polymorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (da) |
| EP (1) | EP2552910B1 (da) |
| JP (1) | JP5802737B2 (da) |
| KR (1) | KR101792621B1 (da) |
| CN (1) | CN102918038B (da) |
| CA (1) | CA2795109C (da) |
| DK (1) | DK2552910T3 (da) |
| ES (1) | ES2538085T3 (da) |
| GB (1) | GB201005623D0 (da) |
| HR (1) | HRP20150513T1 (da) |
| HU (1) | HUE026442T2 (da) |
| ME (1) | ME02102B (da) |
| MX (1) | MX2012011382A (da) |
| PL (1) | PL2552910T3 (da) |
| PT (1) | PT2552910E (da) |
| RS (1) | RS53956B1 (da) |
| RU (1) | RU2559633C2 (da) |
| SI (1) | SI2552910T1 (da) |
| SM (1) | SMT201500107B (da) |
| WO (1) | WO2011121308A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| US10413519B2 (en) | 2015-07-22 | 2019-09-17 | Anavex Life Sciences Corp. | Crystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| AU8592598A (en) | 1997-07-30 | 1999-02-22 | Wyeth | Tricyclic vasopressin agonists |
| PT1000062E (pt) | 1997-07-30 | 2004-12-31 | Wyeth Corp | Agonistas triciclicos de vasopressina |
| EP1149104B1 (en) | 1999-02-04 | 2002-12-11 | Wyeth | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| CA2358895A1 (en) | 1999-02-04 | 2000-08-10 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| WO2000046227A1 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
| DK1149096T3 (da) | 1999-02-04 | 2003-04-07 | Wyeth Corp | Tricykliske pyridin-N-oxider som vasopressinagonister |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en active Application Filing
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko active IP Right Grant
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 DK DK11714079T patent/DK2552910T3/da active
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 RS RS20150258A patent/RS53956B1/en unknown
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
- 2015-05-13 HR HRP20150513TT patent/HRP20150513T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102918038A (zh) | 2013-02-06 |
| KR101792621B1 (ko) | 2017-11-02 |
| EP2552910B1 (en) | 2015-03-11 |
| RS53956B1 (en) | 2015-08-31 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
| PL2552910T3 (pl) | 2015-07-31 |
| EP2552910A1 (en) | 2013-02-06 |
| CA2795109A1 (en) | 2011-10-06 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| US20140296213A1 (en) | 2014-10-02 |
| MX2012011382A (es) | 2013-01-29 |
| GB201005623D0 (en) | 2010-05-19 |
| PT2552910E (pt) | 2015-05-13 |
| JP5802737B2 (ja) | 2015-11-04 |
| CA2795109C (en) | 2018-04-17 |
| HRP20150513T1 (hr) | 2015-06-05 |
| ES2538085T3 (es) | 2015-06-17 |
| JP2013523706A (ja) | 2013-06-17 |
| KR20130023218A (ko) | 2013-03-07 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| CN102918038B (zh) | 2015-09-09 |
| ME02102B (me) | 2015-10-20 |
| HUE026442T2 (en) | 2016-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2552910T3 (da) | Ny polymorf | |
| AU2012331395B2 (en) | Ivabradine hydrochloride form IV | |
| WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
| WO2015003571A1 (zh) | 达拉菲尼甲磺酸盐的新晶型及其制备方法 | |
| ZA200508640B (en) | Crystal of benzimidazole derivative and process for producing the same | |
| RU2594164C2 (ru) | Способ получения 1-(2-метил-4-(2,3,4,5-тетрагидро-1-бензазепин-1-илкарбонил)бензилкарбамоил)-l-пролин-n,n-диметиламида | |
| EP2547681B1 (en) | Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3-metyhl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide | |
| US20200283381A1 (en) | Solid state forms of elafibranor | |
| TWI324517B (en) | 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms | |
| US20070208072A1 (en) | Maleate salt of tegaserod and crystalline forms thereof | |
| CN109336881B (zh) | 一种利伐沙班晶体 | |
| WO2023123742A1 (zh) | PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法 |